Amiksin - instructions for use, doses, side effects, contraindications

Tiloron - 60 mg or 125 mg. Excipients: core: Potato starch - 25,500 mg or 46,000 mg, microcrystalline cellulose - 60,000 mg or 120,000 mg, povi- don-COA (Kollidon 30) - 1,500 mg or

3.000 mg, calcium stearate - 1,500 mg or 3,000 mg sodium croscarmellose (primelloza) - 1,500 mg or 3,000 mg;

Sheath: hypromellose (hydroxypropylmethylcellulose) - Or 3.4050 mg 6.8100 mg of titanium dioxide - 1.7815 mg or 3.5630 mg macrogol 4000 (polyethylene glycol 4000) - 0.4565 mg or 0.9130 mg polysorbate-80 (tvin- 80) - 0.0570 mg or 0.1140 mg, dye quinoline yellow (E 104) - 0.1235 mg or 0.2470 mg, sunset yellow dye (E IN) - 0.1765 mg or 0.3530 mg.

Description:

The tablets covered with a film cover of orange color, round, biconcave. On a broken orange color, slight inclusions of orange and white are allowed.

Pharmacotherapeutic group:antiviral immunostimulating means - inducer of the formation of interferons.

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:A low-molecular synthetic interferon inducer that stimulates the formation of all types of interferons in the body (alpha, beta, gamma and lambda). The main producers of interferon in response to the introduction of Tyloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence of the intestine - liver - blood after 4-24 hours. Amiksin ® has an immunomodulatory and antiviral effect.

In human leukocytes induces synthesis interferon. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers.

Effective against various viral infections, including against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpoviruses. The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, resulting in the suppression of virus reproduction

Pharmacokinetics:

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins. The drug is practically unchanged through the intestine (70%) and through the kidneys (9%). The half-life (T1/2) - 48 h. The drug is not biotransformation and does not accumulate in the body.

Indications:

In children older than 7 years:

for the treatment of influenza and other acute respiratory infections.

In adults (over 18 years):

treatment and prevention of influenza and other ARVI;
treatment of viral hepatitis A, B and C;
treatment of herpetic and cytomegalovirus infection;
in the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, etc.);
in the complex therapy of urogenital and respiratory chlamydia;
in the complex therapy of pulmonary tuberculosis.

Contraindications:

Hypersensitivity to the drug. Pregnancy and lactation. Children under 7 years.

Pregnancy and lactation:

The use of the drug during pregnancy is contraindicated. If you need to use the drug during lactation, breastfeeding should be discontinued.

Dosing and Administration:

Amiksin is taken orally after eating.

For children older than 7 years:

In uncomplicated forms of influenza and other acute respiratory viral infections, 60 mg once a day on the 1 st, 2 nd and 4 th days after the start of treatment. The course dose is 180 mg (3 tablets). When complications of influenza or other acute respiratory viral infections occur, 60 mg once a day on the 1 st, 2 nd, 4 th and 6 th days from the beginning of treatment. The course dose is 240 mg (4 tablets).

For adults (over 18 years):

For treatment of influenza and other acute respiratory viral infections, 125 mg daily for the first 2 days of treatment, then 125 mg after 48 hours. On the course - 750 mg (6 tablets).

For the prevention of influenza and other acute respiratory viral infections, 125 mg once a week for 6 weeks. On the course - 750 mg (6 tablets).

For treatment of herpetic, cytomegalovirus infection, the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25-2.5 g (10-20 tablets). For non-specific prophylaxis of viral hepatitis A, 125 mg once a week for 6 weeks.

For the treatment of viral hepatitis A - 125 mg twice a day on the first day, then 125 mg after 48 hours. The course - 1.25 g (10 tablets).

For the treatment of acute hepatitis B - the first two days of 125 mg, then 125 mg after 48 hours, for treatment - 2 g (16 tablets). With protracted hepatitis AT - 125 mg twice a day on the first day, then 125 mg after 48 hours. The course of treatment - 2.5 g (20 tablets).

With chronic hepatitis B - the initial phase of treatment (2.5 g - 20 tablets) - the first two days for 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (from 1.25 g - 10 tablets to 2.5 g - 20 tablets) - 125 mg per week. The course dose of Amiksin® is from 3.75 g to 5 g, the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies reflecting the degree of activity of the process. In acute hepatitis C, 125 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The course of treatment is 2.5 g (20 tablets). In chronic hepatitis C - the initial phase of treatment (2.5 g - 20 tablets) - the first two days of 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (2.5 g - 20 tablets) - 125 mg per week. The course dose of Amiksin® is 5 g, the duration of therapy is 6 months, depending on the results of biochemical, immunological, and morphological markers of the activity of the process.

In the complex treatment of neuroviral infections - 125-250 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

With urogenital and respiratory chlamydiosis, the first two days of 125 mg, then 48 hours after 125 mg. Coursework e1.25 g (10 tablets).

With complex therapy of tuberculosis,250 mg of the first two days of treatment, then 125 mg after 48 hours. Coursework a dose of 2.5 g (20 tablets).

Side effects:Possible allergic reactions, dyspeptic phenomena, short-term chills. <

Overdose:

Cases of drug overdose are not known.

Interaction:Compatible with antibiotics and drugs traditional treatment of viral and bacterial diseases. Clinically significant interaction of Amiksin® with antibiotics and traditional treatment of viral and bacterial diseases has not been revealed.

Effect on the ability to drive transp. cf. and fur:The drug does not adversely affect the ability to manage transport and other potentially hazardous activities,requiring increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:Tablets, film-coated 60 mg, 125 mg.

Packaging:For 6 or 10 tablets in a planar cell package; 6, 10 or 20 tablets in a polymer can.

1 or 2 contourcell packs or 1 can of polymer with instructions for use in a pack of cardboard.

Storage conditions:

3 years. Do not use at the expiration date indicated on the package, storage conditions

Shelf life:

List B. In dry the dark place at a temperature of no higher than 30 ° C.

Keep out of the reach of children.

Conditions of leave from pharmacies

Without a prescription - tablets 125 mg, covered with a film membrane.

Prescription - 60 mg tablets, covered with a film membrane.

Terms of leave from pharmacies:On prescription

Registration number:LSR-000175/08

Date of registration:24.01.2008

The owner of the registration certificate:PHARMSTANDART-TOMSKHIMFARM, OJSC PHARMSTANDART-TOMSKHIMFARM, OJSC Russia

Manufacturer: & nbsp

PHARMSTANDART-TOMSKHIMFARM, OJSC Russia

Representation: & nbspPHARMSTANDART JSC PHARMSTANDART JSC Russia

Information update date: & nbsp30.07.2015

Illustrated instructions

Instructions

Amiksin® (Amixin)